埃诺格鲁肽凭借独特的偏向性机制，在多项临床研究中展现出了优异的疗效与安全性，其中国人群经安 慰剂组调整后的平均体重降幅达15.1%，92.8%的患者达到具有临床意义的体重下降，超过80%的患者血 糖达标(HbA1c <7.0%)。 先为达生物创始人、CEO 潘海博士表示此次与辉瑞中国达成战略合作，期待能将先为达生物的创新科 学成果与辉瑞中国顶尖的商业化能力深度融合，共同推动埃诺格鲁肽的商业化进程。双方将以'体重管 理年'为重要契机，携手为中国肥胖及代谢性疾病患者带来更多元、更优质的治疗选择。" 先为达生物与辉瑞中国宣布，双方就埃诺格鲁肽注射液达成商业化战略合作协议。埃诺格鲁肽注射液是 全球首个获批上市的cAMP偏向型GLP-1受体激动剂，已于2026年1月获得国家药品监督管理局(NMPA) 批准上市用于成人2型糖尿病的治疗，其成人长期体重管理适应症的上市许可申请已获NMPA受理。 根据协议，辉瑞将获得该产品在中国大陆的独家商业化权益，先为达生物为许可产品的药品上市许可持 有人(MAH)，负责许可产品的研发、注册、生产及供应。先为达生物将有权获得辉瑞支付的最高可达 4.95亿美元的付款总额，包括首付款、注册及销 ...

辉瑞获得埃诺格鲁肽中国大陆独家商业化权益 继诺和诺德、礼来之后，中国的减肥药市场要添加新的跨国巨头玩家了。 2月24日，先为达生物宣布与辉瑞中国达成商业化战略合作协议。 根据协议，辉瑞将获得先为达生物新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液（埃诺格鲁肽）在 中国大陆的独家商业化权益；同时先为达生物为许可产品的药品上市许可持有人，负责许可产品的研 发、注册、生产及供应。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付 款、注册及销售里程碑付款。 作为国产长效GLP-1受体激动剂，埃诺格鲁肽的降糖适应证已于今年1月份获批中国上市，其成人长期 体重管理适应证的上市许可申请也获中国药监局受理。 辉瑞全球高级副总裁、中国区总裁Jean-Christophe Pointeau表示，当前中国成人肥胖率为14.1%，并且 与"三高"等代谢性疾病密切相关。"健康体重管理"已被正式纳入健康中国行动，此次合作正是辉瑞积极 响应该战略的具体实践。 肥胖是一种复杂的慢性疾病，是心血管疾病、2型糖尿病及部分癌症等非传染性疾病的重要诱因，也会 加重传染性疾病患者的病情。GLP-1（胰高血糖素样肽-1）类药物 ...

智通财经APP获悉，美国制药巨头辉瑞公司(PFE.US)与本土初创企业杭州先为达生物科技股份有限公司 达成协议，以获得后者一款减肥疗法在中国的独家商业化权益，此举旨在强化其在高增长减肥市场的布 局。 辉瑞正寻求在后疫情时代进行业务重建。由于许多核心产品面临更激烈的竞争，且其最初进军减肥药市 场的尝试受挫，该公司面临寻找新收入来源的压力。 与先为达的合作亦有望提振辉瑞的中国业务。据了解，截至2024年，中国业务占辉瑞总收入的4%，但 在过去几年中经历了多轮重组。在中国减肥药市场，辉瑞将直面全球制药巨头及信达生物等本土竞争对 手的挑战。 先为达的ecnoglutide与诺和诺德的司美格鲁肽(Ozempic)作用机理相似，均通过模拟一种名为胰高血糖素 样肽-1(GLP-1)的天然激素来调节血糖和抑制食欲。但该公司认为，该药物略有不同的结构使其比其他 GLP-1受体激动剂更有效、更安全。在一项后期研究中，ecnoglutide实现了与礼来公司的替尔泊肽 (Zepbound)相媲美的减重效果。 根据一份声明，双方达成的交易涉及药物ecnoglutide。该药近期在中国获批用于治疗糖尿病，目前其用 于减肥的适应症正处于监 ...

2月24日，辉瑞中国与杭州先为达生物（以下简称先为达生物）宣布，双方就新一代偏向型GLP-1受体 激动剂埃诺格鲁肽注射液（英文：Ecnoglutide injection，以下简称：埃诺格鲁肽）达成商业化战略合作 协议。根据协议，辉瑞将获得该产品在中国大陆的独家商业化权益，迈出其全球代谢领域战略布局在中 国的第一步；同时先为达生物为许可产品的药品上市许可持有人（MAH），负责许可产品的研发、注 册、生产及供应。 先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付 款。埃诺格鲁肽是由先为达生物自主研发的新一代cAMP偏向型GLP-1受体激动剂，将为2型糖尿病及长 期体重管理相关患者提供更为精准的治疗方案。 ...

本报讯(记者李静) 辉瑞国际市场首席商务官、执行副总裁AlexandredeGermay(安卓远)表示："此次合作标志着辉瑞在推进 全球代谢领域战略方面迈出了又一坚实的重要一步，也彰显了辉瑞致力于在新一代慢性体重管理疗法领 域发挥重要领导作用的长期承诺。在最近完成对Metsera的收购，以及与药友制药达成新的全球独家合 作与许可协议后，我们非常高兴能够与像先为达生物这样充满活力的本土创新企业携手合作。未来我们 将继续把资源投入到这一最具影响力和高增长潜力的治疗领域，目标是加速将这些重要的创新疗法带给 全球患者，满足未被满足的患者需求。" 2月24日，杭州先为达生物科技股份有限公司(以下简称"先为达生物")与辉瑞中国宣布，双方就新一代 偏向型GLP-1受体激动剂埃诺格鲁肽注射液(英文：Ecnoglutideinjection，以下简称：埃诺格鲁肽)达成商 业化战略合作协议。根据协议，辉瑞将获得该产品在中国大陆的独家商业化权益，迈出其全球代谢领域 战略布局在中国的第一步；同时先为达生物为许可产品的药品上市许可持有人(MAH)，负责许可产品的 研发、注册、生产及供应。先为达生物将有权获得辉瑞支付的最高可达4.95亿 ...

Core Insights - Pfizer has entered a licensing agreement with Sciwind Biosciences for the type 2 diabetes treatment ecnoglutide, with potential payments reaching up to $495 million based on milestone achievements [1] - This deal is a strategic move for Pfizer to enhance its presence in the metabolic field within China [1] - Ecnoglutide is part of the GLP-1 receptor agonists class, which has attracted investments from various pharmaceutical companies [1] Company Developments - Sciwind Biosciences has received approval for ecnoglutide in China as of January and is also pursuing approval for an experimental version aimed at weight management [1] - The agreement includes an upfront fee and additional payments linked to regulatory and sales milestones, specifically for the commercialization of ecnoglutide in mainland China [1] - Unlike competitors' products, ecnoglutide will not be included in China's state-run health insurance for type 2 diabetes treatments [1]

2月24日消息，杭州先为达生物科技股份有限公司与辉瑞中国今日宣布，双方就新一代偏向型GLP-1受 体激动剂埃诺格鲁肽注射液（英文：Ecnoglutide injection，以下简称：埃诺格鲁肽）达成商业化战略合 作协议。 据悉根据上述协议，辉瑞将获得该产品在中国大陆的独家商业化权益，迈出其全球代谢领域战略布局在 中国的第一步；同时先为达生物为许可产品的药品上市许可持有人（MAH），负责许可产品的研发、 注册、生产及供应。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、 注册及销售里程碑付款。 2月24日消息，杭州先为达生物科技股份有限公司与辉瑞中国今日宣布，双方就新一代偏向型GLP-1受 体激动剂埃诺格鲁肽注射液（英文：Ecnoglutide injection，以下简称：埃诺格鲁肽）达成商业化战略合 作协议。 据悉根据上述协议，辉瑞将获得该产品在中国大陆的独家商业化权益，迈出其全球代谢领域战略布局在 中国的第一步；同时先为达生物为许可产品的药品上市许可持有人（MAH），负责许可产品的研发、 注册、生产及供应。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首 ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and m ...

Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of enabling technologies and services for the global pharmaceutical and chemical industries, is pleased to announce the installation of its second Self-Driving Laboratory ("SDL") at Pfizer, as part of the multi-year agreement between the companies. The installation was completed in January 2026.TRANSACTION HIGHLIGHTSThe present SDL ...

Core Viewpoint - The article highlights five dividend stocks that are currently attractive for income-focused investors, particularly in light of overvalued growth stocks. Group 1: PepsiCo - PepsiCo is recommended over Coca-Cola due to its higher forward-looking dividend yield of 3.5% compared to Coke's 2.6% [4] - The company's stock has underperformed due to challenges in its food and snack business, but initiatives like healthier product options are positively impacting its financials [4] Group 2: Pfizer - Pfizer's revenue peaked at over $100 billion in 2022 due to COVID-19 but has since declined as the company focused on pandemic response [5] - The company plans to launch eight new blockbuster drugs by 2030, which could increase annual revenue from around $60 billion to $80 billion [7] - Pfizer's current dividend yield is 6.3%, making it an attractive option for income investors [8] Group 3: Realty Income - Realty Income is a REIT that has consistently paid monthly dividends since 1969 and has raised its per-share payment for over 31 years [10] - The REIT focuses on brick-and-mortar retail, with a high occupancy rate of 98.7%, indicating resilience despite challenges in the retail sector [11] Group 4: Verizon - Verizon offers a forward-looking dividend yield of 5.8% and has increased its quarterly payment for 19 consecutive years [12] - The company's strong customer dependency on mobile services supports its stable income generation [14] Group 5: IBM - IBM has a dividend yield of 2.6% and has raised its payment annually for the past 30 years [15] - A significant portion of IBM's revenue comes from high-margin software and consulting services, with annualized recurring revenue from software subscriptions at $23.6 billion [18]